Given our data showing that HIF-1α inhibition alleviates the tumor-promoting effect of GSTZ1 deficiency on HCC angiogenesis, we propose that a therapeutic strategy that suppresses SA-activated HIF-1α may improve current therapies that have limited effect on abnormal vasculature. The gene discussed is GSTZ1; the disease is neoplasm.